Import from '@/components/mdx'

Intrarosa vs Combipatch / Climara Pro: What the Real-World Evidence Actually Shows

What Are These Drugs and Why Are They Compared?

Women dealing with menopause symptoms often land in one of two clinical situations: their biggest complaint is vaginal dryness and painful sex, or they are managing a full constellation of hot flashes, sleep disruption, and vaginal symptoms simultaneously. That distinction drives the comparison between Intrarosa and the combination estrogen-progestogen patches Combipatch and Climara Pro.

Intrarosa delivers prasterone, a synthetic form of DHEA, directly to vaginal tissue as a 6.5 mg nightly insert. Inside vaginal cells, DHEA is converted locally to estrogens and androgens through intracrinology, a process where peripheral tissues produce sex steroids from precursors without depending on the ovaries. This means systemic circulating estradiol levels remain in the normal postmenopausal range during Intrarosa use, a finding confirmed in the Phase 3 trials that supported FDA approval.

Combipatch and Climara Pro take a different approach entirely. Both are transdermal matrix patches that deliver systemic estradiol alongside a progestogen. Combipatch contains norethindrone acetate (0.14 mg/day), while Climara Pro contains levonorgestrel (0.015 mg/day). Because they contain a progestogen, both are indicated only for women who have a uterus; the progestogen component protects the endometrium from the proliferative effect of unopposed estrogen.

Understanding this structural difference answers most questions about switching from one to the other.

The Evidence Base: Where Each Drug Has Been Studied

No published head-to-head randomized controlled trial compares prasterone vaginal inserts to either Combipatch or Climara Pro. This is a genuine evidence gap, and it shapes every clinical recommendation in this article.

Intrarosa: Phase 3 Trial Evidence

The most rigorous evidence for Intrarosa comes from a Phase 3 RCT published in Menopause (2016) that enrolled 422 postmenopausal women and randomized them to daily prasterone 6.5 mg vaginal insert or placebo for 12 weeks. The trial used the four co-primary endpoints required by the FDA for GSM trials: percentage of superficial cells, percentage of parabasal cells, vaginal pH, and the most bothersome symptom score.

Prasterone produced statistically significant improvements on all four endpoints compared to placebo. Mean vaginal pH dropped by 1.0 unit from baseline in the prasterone group versus 0.4 units in the placebo group. The most bothersome symptom, dyspareunia (painful sex), showed a treatment difference of 0.39 on a 3-point scale. The trial found no significant change in serum estradiol, testosterone, or DHEA-sulfate levels beyond the postmenopausal reference range in the prasterone group.

What the prasterone trials did not measure: vasomotor symptoms, bone mineral density, cardiovascular markers, or quality of sleep. These were never endpoints.

Combipatch / Climara Pro: Systemic HRT Evidence

Systemic combination transdermal HRT has a much longer and broader evidence trail. A 2004 controlled trial published in Fertility & Sterility examined continuous combined transdermal estradiol-norethindrone acetate and found significant reductions in hot flash frequency and improvements in vaginal atrophy scores, alongside an endometrial safety profile that showed no hyperplasia at 12 months. That trial used a patch formulation directly comparable to Combipatch.

The Women's Health Initiative (WHI), while it used conjugated equine estrogen rather than transdermal estradiol, established the systemic risk framework that still informs prescribing. Transdermal routes are now recognized to avoid the first-pass hepatic effect, which reduces the risk of venous thromboembolism compared to oral estrogen, though the absolute risk difference is small in younger postmenopausal women.

Real-World Evidence: What Observational Data Show

Real-world prescribing data from insurance claims and pharmacy registries, cited in a 2023 Menopause journal analysis, show that Intrarosa is most commonly initiated in women presenting with dyspareunia as the sole or dominant complaint, often in women who declined or were not offered systemic HRT. Combination patches are more commonly prescribed in women who have multiple symptoms, are earlier in the postmenopausal transition (<5 years from last menstrual period), or have documented bone density loss.

Based on the available evidence, a WomanRx clinical framework for choosing between these options looks like this:

| Clinical Presentation | Preferred Option | Rationale | |---|---|---| | Dyspareunia or vaginal dryness only, no hot flashes | Intrarosa | Local action, no systemic estrogen needed | | Hot flashes + vaginal dryness + intact uterus | Combipatch or Climara Pro | Systemic relief with endometrial protection | | Breast cancer history (current or recent) | Neither without oncology input | Both carry hormone-related considerations | | Uterus absent (hysterectomy) | Intrarosa OR estradiol-only patch | Progestogen unnecessary; broader options available | | Wanting to avoid systemic hormones | Intrarosa | Validated non-systemic mechanism | | Bone density concern | Combipatch / Climara Pro | Systemic estrogen shown to preserve BMD |

Sex-Specific Physiology: How Menopause Changes the Pharmacology

Menopause changes drug behavior in ways that matter for both options.

Vaginal Tissue Changes and Local Drug Delivery

After menopause, declining estrogen causes the vaginal epithelium to thin from its reproductive-years thickness of roughly 25 cell layers to as few as 5 to 10 layers. This thinning alters how Intrarosa is absorbed. DHEA is taken up by vaginal epithelial cells and converted locally by 5-alpha-reductase and aromatase into androgens and estrogens. The epithelial cells essentially do the conversion work, which is why systemic levels remain low. As vaginal tissue responds to treatment and rugae return, the local environment continues to improve drug uptake over weeks.

Systemic patch delivery through skin is also menopause-influenced. Postmenopausal skin tends to be thinner and drier, which may subtly alter transdermal absorption rates for Combipatch and Climara Pro, though manufacturer pharmacokinetic data do not separate pre- and postmenopausal skin data. This is an area where sex-specific data are genuinely thin.

Androgen Status in Postmenopausal Women

One underappreciated aspect of Intrarosa is its androgen component. Postmenopausal women experience a gradual decline in DHEA-S (the sulfate storage form of DHEA) through the fifth and sixth decades. Intrarosa directly supplies DHEA to vaginal tissue, and a portion is converted to testosterone locally. Whether this local androgenic activity contributes to improved sexual desire beyond mechanical improvements in vaginal comfort is biologically plausible but has not been rigorously separated from placebo effects in published RCTs. The American College of Obstetricians and Gynecologists (ACOG) notes in Practice Bulletin 141 that androgen therapy for HSDD in postmenopausal women remains an area of active investigation, not established standard care.

The progestogen in Combipatch (norethindrone acetate) and Climara Pro (levonorgestrel) both have some androgenic activity themselves, which can produce acne or mild hair changes in some women. Levonorgestrel is more androgenic than norethindrone acetate at equivalent progestogen doses. Women with a history of androgenic side effects on oral contraceptives should mention this to their prescriber before starting either patch.

Perimenopause vs. Post-Menopause: Does Life Stage Alter the Choice?

Both drugs are FDA-approved for postmenopausal women only. Intrarosa and the combination patches are not indicated during perimenopause.

During perimenopause, ovarian estrogen production is erratic but not absent. Using a systemic combination patch during this stage risks estrogen excess on high-production days, which can cause breast tenderness, bloating, and irregular bleeding. Intrarosa's local mechanism makes it somewhat less likely to add systemic estrogen on top of endogenous production, but the drug has not been studied in perimenopausal women, and the FDA indication specifies postmenopause.

Women within 2 to 3 years of their final menstrual period (recent menopause) are often the best candidates for systemic HRT because the "timing hypothesis," supported by Menopause Society guidance (2023), suggests cardiovascular benefit or at least neutrality when systemic HRT is started close to the final menstrual period and before age 60. Combination patches offer this window of opportunity; Intrarosa does not, because it does not provide systemic estradiol at therapeutic levels.

Women who are more than 10 years postmenopausal or older than 60 who have never used HRT carry a different benefit-risk profile. Systemic HRT in this group has more evidence of cardiovascular risk. Intrarosa, by staying local, sidesteps much of that concern for women whose only unmet need is vaginal.

Pregnancy, Lactation, and Contraception: Required Safety Information

Both drugs are contraindicated in pregnancy. Neither should be used during lactation.

Intrarosa in Pregnancy and Lactation

Intrarosa (prasterone) is FDA Pregnancy Category X. Animal studies showed virilization of female fetuses exposed to androgens in utero. While postmenopausal women are not becoming pregnant through natural conception, this matters for two reasons: women in surgical menopause who are younger than 40 occasionally conceive via donor egg embryo transfer, and the labeling applies regardless of the mechanism of pregnancy.

No human lactation data exist for vaginal prasterone. Androgen precursors do transfer into human milk based on physiology, so breastfeeding is not recommended during use, though the clinical scenario of a lactating woman needing postmenopausal GSM treatment is rare.

Contraception note: Natural postmenopausal women do not require contraception with either drug. Women in premature ovarian insufficiency who retain any ovarian function, or women who have undergone menopause due to chemotherapy where ovarian recovery is possible, should confirm with their prescriber whether contraception remains relevant before starting either treatment.

Combipatch / Climara Pro in Pregnancy and Lactation

Systemic estradiol-progestogen patches are contraindicated in pregnancy. Exogenous progestogens were historically associated with congenital anomaly concerns, though modern data are largely reassuring for brief inadvertent first-trimester exposure. The norethindrone in Combipatch and levonorgestrel in Climara Pro both cross the placenta; deliberate use is not acceptable. Both drugs are also not recommended during breastfeeding because estrogen suppresses prolactin and reduces milk supply, and progestogen transfer into milk carries theoretical infant exposure risk.

Side Effects: How They Differ by Drug and by Woman

Intrarosa Side Effects

The most commonly reported adverse event in Intrarosa trials was vaginal discharge, occurring in roughly 5% to 7% of women. This reflects the dissolving suppository base, not infection. A small number of women report mild vaginal irritation in the first week of use.

Because systemic absorption is minimal, systemic estrogen side effects such as breast tenderness, headache, and bloating are not expected and were not elevated above placebo rates in the Phase 3 trial. Women who have had breast cancer are sometimes offered Intrarosa when vaginal symptoms are severe, though this decision requires oncology guidance and is not a blanket recommendation from any major guideline as of 2025.

Combipatch and Climara Pro Side Effects

Combination patches produce a wider side-effect profile, consistent with systemic hormone delivery.

Skin reactions at the patch site occur in roughly 14% to 20% of users, ranging from mild redness to contact dermatitis. Rotating sites reduces this risk.

Breast tenderness is common in the first 1 to 3 months, particularly with Combipatch, which uses norethindrone acetate. Irregular spotting or breakthrough bleeding occurs in a subset of women using continuous combined regimens, usually resolving by month 3 to 6. Women with persistent or heavy bleeding after 6 months of continuous combined use require endometrial evaluation.

The androgenic side effects of levonorgestrel (Climara Pro) include acne and oily skin in a minority of users. Norethindrone acetate (Combipatch) is generally considered intermediate in androgenicity.

Switching from Intrarosa to Combipatch or Climara Pro (or Vice Versa)

Women switch between these drugs for predictable reasons: new symptoms emerge (hot flashes appear after starting Intrarosa), side effects become intolerable, or insurance formulary changes force a substitution.

Switching from Intrarosa to a Combination Patch

If you are using Intrarosa and now have significant hot flashes or sleep disruption, adding or switching to a systemic patch is clinically logical. You do not need a washout period; Intrarosa's local tissue effects do not create systemic hormone levels that would interact with the patch.

If you have a uterus and switch to Combipatch or Climara Pro, you no longer need a separate progestogen because the patch contains one. If you were using oral progesterone or a progestogen IUD alongside Intrarosa, clarify the plan for that component with your prescriber.

Switching from a Combination Patch to Intrarosa

Some women switch to Intrarosa because hot flashes have resolved and only vaginal symptoms persist, or because systemic HRT was stopped for a medical reason (new VTE, breast density change, or personal preference). When switching from a combination patch to Intrarosa, vasomotor symptoms may return within 1 to 4 weeks as systemic estradiol clears. Prepare for this and have a plan with your prescriber.

After stopping a combination patch, if you have a uterus, you do not need to continue the progestogen because Intrarosa does not stimulate the endometrium.

Who This Is Right For (and Not Right For)

Intrarosa Is Most Appropriate If You

• Are postmenopausal with moderate-to-severe dyspareunia or vaginal dryness as your primary complaint
• Do not have significant hot flashes or night sweats
• Prefer to avoid systemic hormone exposure
• Have a history that makes systemic estrogen complicated (personal or strong family history of breast cancer should involve oncology in the decision)
• Are in late postmenopause and are not a candidate for systemic HRT

Intrarosa Is Not the Right Choice If You

• Need vasomotor symptom relief
• Have bone density loss that requires pharmacological prevention or treatment
• Are in the early menopause window where systemic HRT may offer cardiovascular timing benefit
• Have only mild or no GSM symptoms

Combipatch or Climara Pro Is Most Appropriate If You

• Have both vasomotor and genitourinary symptoms
• Are within 10 years of your final menstrual period and younger than 60
• Have a uterus (both patches include endometrial protection)
• Have documented bone loss or high fracture risk
• Prefer twice-weekly (Combipatch) or once-weekly (Climara Pro) dosing over nightly vaginal use

Combination Patches Are Not the Right Choice If You

• Have a personal history of VTE, active liver disease, or unexplained vaginal bleeding
• Have had a hormone-receptor-positive breast cancer (requires oncology discussion, not automatic exclusion but not routine prescribing either)
• Had a hysterectomy and prefer estradiol alone (a progestogen is unnecessary and adds side-effect burden without benefit in women without a uterus)
• Prefer to avoid any systemic hormone exposure

Evidence Gaps and What We Still Do Not Know

Women have been historically underrepresented in drug trials across medicine, and menopause research is no exception. Several specific evidence gaps are worth naming.

First, no published RCT has directly compared vaginal prasterone to any systemic combination patch. All comparisons are indirect, based on separate trial arms against placebo.

Second, the long-term cardiovascular and breast cancer safety data for Intrarosa are thin. The Phase 3 program ran for 12 weeks, with a 52-week safety extension study. Five-plus year data comparable to the WHI simply do not exist for prasterone. The Menopause Society 2023 position statement on hormone therapy acknowledges that vaginal DHEA has an acceptable short-term safety profile but calls for longer follow-up data.

Third, the sex-specific pharmacokinetic data for transdermal patches in women across the BMI spectrum are limited. Women with BMI above 35 may have altered patch adhesion, different dermal blood flow, and different subcutaneous fat depth, all of which could affect delivery. ACOG Practice Bulletin 141 does not stratify HRT recommendations by BMI, and the trials largely did not either.

Fourth, racial and ethnic diversity in the trial populations for both drug classes has been inadequate. Vasomotor symptom prevalence and severity vary by race and ethnicity based on the SWAN (Study of Women's Health Across the Nation) cohort, yet dose-finding and efficacy trials do not reflect that diversity.

Practical Dosing, Application, and Monitoring

Intrarosa Dosing and Use

The approved dose is one 6.5 mg vaginal insert (applicator provided) inserted nightly at bedtime. FDA prescribing information does not describe a dose titration schedule. Some women notice improvement in vaginal moisture within 2 to 4 weeks; dyspareunia improvement typically requires 8 to 12 weeks of consistent use.

No routine serum hormone monitoring is required because systemic levels remain in the postmenopausal range. Pelvic examination at baseline to confirm atrophy and rule out other causes of dyspareunia is reasonable clinical practice.

Combipatch and Climara Pro Dosing and Use

Combipatch is applied twice weekly to the lower abdomen or buttocks (not breasts). The standard starting dose delivers 0.05 mg estradiol plus 0.14 mg norethindrone acetate daily. A lower-dose option (0.05/0.25 mg per patch) is available.

Climara Pro is applied once weekly. It delivers 0.045 mg estradiol and 0.015 mg levonorgestrel daily. Consistent patch placement, rotating sites within the approved areas, and pressing firmly for 10 seconds improve adhesion.

Serum estradiol levels can be checked 2 weeks after starting if there is uncertainty about absorption, though The Menopause Society recommends dosing to symptom relief rather than to a target serum level.

Endometrial surveillance (transvaginal ultrasound or endometrial biopsy) is indicated for persistent irregular bleeding beyond 6 months on continuous combined therapy, not as routine annual monitoring.